Aluminum hydroxide associated to Schistosoma mansoni 22.6 kDa protein abrogates partial protection against experimental infection but not alter interleukin-10 production

Memorias do Instituto Oswaldo Cruz

Volumn 101, Issue SUPPL. 1, 2006, Pages 365-368

  Pacífico, Lucila G G ^a   Fonseca, Cristina T ^a   Barsante, Michele M ^a   Cardoso, Luciana S ^b   Araújo, Maria Ilma ^b   Oliveira, Sérgio C ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Adjuvant; Aluminum hydroxide; Interleukin 10; Recombinant vaccine; Schistosoma mansoni; Sm22.6

Indexed keywords

MUS; SCHISTOSOMA MANSONI;

EID: 33846416547     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/S0074-02762006000900060     Document Type: Conference Paper

References (21)

1. Broderson JR 1989. A retrospective review of lesions associated with the use of Freund's adjuvant. Lab Anim Sci 39: 400-405.
2. Cardoso FC, Pacífico RNA, Mortara RA, Oliveira SC 2006. Human antibody responses of patients living in endemic areas for schistosomiasis to the tegumental protein Sm29 identified through genomic studies. Clin Exp Immunol 144: 382-391.
3. Claassen E, de Leeuw W, de Greeve P, Hendriksen C, Boersma W 1992. Freund's complete adjuvant: an effective but disagreeable formula. Res Immunol 143: 478-483.
4. Chitsulo L, Engels D, Montresor A, Savioli L 2000. The global status of schistosomiasis and its control. Acta Trop 77: 41-51.
5. Coulson PS 1997. The radiation-attenuated vaccine against schistosomes in animal models: paradigma for human vaccine? Adv Parasitol 39: 271-336.
6. Doenhoff MJ, Kusel JR, Coles GC, Cloll D 2002. Resistance of Schistosoma mansoni to praziquantel: is there a problem? Trans R Soc Trop Med Hyg 96: 465-469.
7. Dunne DW, Webster M, Smith P, Langley JG, Richardson BA, Fulford AJ, Butterworth AE, Sturrock RF, Kariuki HC, Ouma JH 1997. The isolation of a 22 kDa band after SDS-PAGE of Schistosoma mansoni adult worms and its use to demonstrate that IgE responses against the antigen(s) it contains are associated with human resistance to reinfection. Parasite Immunol 19: 79-89.
8. Fonseca CT, Brito CF, Alves JB, Oliveira SC 2004. IL-12 enhances protective immunity in mice engendered by immunization with recombinant 14 kDa Schistosoma mansoni fatty acid-binding protein through an IFN-gamma and TNF-alpha dependent pathway. Vaccine 2: 503-510
9. Fonseca CT, Cunha-Neto E, Goldberg AC, Kalil J, de Jesus AR, Carvalho EM, Correa-Oliveira R, Hammer J, Sidney J, Sette A, Oliveira SC 2005. Identification of paramyosin T cell epitopes associated with human resistance to Schistosoma mansoni reinfection. Clin Exp Immunol 142: 539-547.
10. Jankovic D, Wynn TA, Kullberg MC, Caspar R, James S, Cheever AW, Sher A 1999. Optimal vaccination against Schistosoma mansoni requires the induction of both B cell and IFNg dependent effector mechanisms. J Immunol 162: 345-351.
11. King CL 2001. Initiation and regulation of disease in schistosaomiasis. In AAF Mahmoud, Schistosomiasis, Imperial College Press, London, p. 213-264.
12. Kleinman NR, Kier AB, Diaconu E, Lass JH 1993. Posterior paresis induced by Freund's adjuvant in guinea pigs. Lab Anim Sci 43: 364-366.
13. Pacífico LGG, Fonseca CT, Chiari L, Oliveira SC 2006. Immunization with Schistosoma mansoni 22.6 kDa antigen induces partial protection against experimental infection in a recombinant protein form but not as DNA vaccine. Immunobiology 211: 97-104
14. Santiago ML, Hafalla JC, Kurtis JD, Aligui GL, Wiest PM, Olveda RM, Olds GR, Dunne DW, Ramirez BL 1998. Identification of the Schistosoma japonicum 22.6-kDa antigen as a major target of the human IgE response: similarity of IgE-binding epitopes to allergen peptides. Allergy Immunol 117: 94-104.
15. Smithers SR, Terry RJ 1965. The infection of laboratory hosts with cercariae of Schistosoma mansoni and recovery of adult worms. Parasitology 55: 695-700.
16. Stein LD, David JR1988. Cloning of a developmentally regulated tegument antigen of Schistosoma mansoni. Mol Biochem Parasitol 20: 253-264.
17. Steiner JW, Langer B, Schatz DL 1960. The local and systemic effects of Freund's adjuvant and its fractions. Arch Pathol 70: 424-434.
18. Verjovski-Almeida S, DeMarco R, Martins EA, Guimarães PE, Ojopi EP, Paquola AC, Piazza JP, Nishiyama Jr MY, Kitajima JP, Adamson RE, Ashton, PD, Bonaldo MF, Coulson PS, Dillon GP, Farias LP, Gregorio SP, Ho PL, Leite RA, Malaquias LC, Marques RC, Miyasato PA, Nascimento AL, Ohlweiler FP, Reis EM, Ribeiro MA, Sa RG, Stukart GC, Soares MB, Gargioni C, Kawano T, Rodrigues V, Madeira AM, Wilson RA, Menck CF, Setubal JC, Leite LC, Dias-Neto E 2003 Transcriptome analysis of the acoelomate human parasite Schistosoma mansoni. Nat Genet 35: 148-157.
19. Webster M, Fulford AJ, Braun G, Ouma JH, Kariuki HC, Havercroft JC, Gachuhi K, Sturrock RF, Butterworth AE, Dunne DW 1996. Human immunoglobulin E responses to a recombinant 22.6-kilodalton antigen from schistosomiasis mansoni adult worms are associated with low intensities of reinfection after treatment. Infect Immun 64: 4042-4046.
20. Wynn TA, Hoffmann KF 2000. Defining a schistosomiasis vaccination strategy - is it really Th1 versus Th2? Parasitol Today 16: 497-501.
21. Zouain CS, Gustavson S, Oliveira SC, Azevedo V, Alves JB, Goes AM 2001. The role of IL-10 and IgG1 in the protection and granulomatous response in Schistosoma mansoni P24-immunized mice. Vaccine 19: 1218-1224.